Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide Dosing in Early RA (LEADER)
NCT00596206Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2007
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of leflunomide in rheumatoid arthritis (RA) (2 arms), sponsored by Sanofi. Primary endpoint: American College of Rheumatology 20% Response Rate at 3 months. Started Dec 2007; status: completed.
02
Drugs
leflunomide
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00596206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00596206.